Transplantation adjuvant in cell therapy using neural progenitor cells
The present invention provides a transplantation adjuvant for neural progenitor cells containing valproic acid and/or zonisamide as an active ingredient.
1. A method of treating a degenerative disease of dopaminergic neurons in a subject in need thereof, comprising
transplanting neural progenitor cells in the subject, and
administering zonisamide to the subject before, after, or simultaneously with the transplanting,
wherein the method excludes administering valproic acid.
2. The method according to claim 1 , wherein the administering is performed no sooner than two days before the transplanting.
3. The method according to claim 1 , wherein the neural progenitor cells are derived from iPS cells.
4. The method according to claim 1 , wherein the degenerative disease of dopaminergic neurons is Parkinson's disease.
5. The method according to claim 1 , wherein the administering is performed before the transplanting.
6. The method according to claim 1 , wherein the administering is performed after the transplanting.
7. The method according to claim 2 , wherein the administering is performed after the transplanting.
8. The method according to claim 1 , wherein the subject is human.
9. The method according to claim 1 , wherein the zonisamide is administered in an amount effective to increase a graft survival rate of dopaminergic neurons induced from the neural progenitor cells.
10. The method according to claim 1 , wherein the zonisamide is administered in an effective amount from 10 to 600 mg per day of the zonisamide.
11. The method according to claim 1 , wherein the zonisamide is administered in an amount that is more than 25 mg and 600 mg or less per day of the zonisamide.
12. A method of improving retention rate of dopaminergic nerve cells induced from neural progenitor cells after transplantation, comprising
transplanting neural progenitor cells in a subject, and
administering an effective amount of zonisamide to the subject before, after, or simultaneously with the transplanting wherein the method excludes administering valproic acid.
13. The method according to claim 12 , wherein the administering is performed no sooner than two days before the transplanting.
14. The method according to claim 12 , wherein the neural progenitor cells are derived from iPS cells.
15. A method of treating a degenerative disease of dopaminergic neurons, comprising the method of improving retention rate of dopaminergic nerve cells induced from neural progenitor cells after transplanting according to claim 12 .
16. The method according to claim 15 , wherein the degenerative disease of dopaminergic neurons is Parkinson's disease.
17. The method according to claim 12 , wherein the administering is performed before the transplanting.
18. The method according to claim 12 , wherein the administering is performed after the transplanting.
19. The method according to claim 12 , wherein the subject is human.